ClinicalTrials.gg
WithdrawnNCT02539615Updated Jan 25, 2016

A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old

A Phase 3 interventional study of ForeCYTE Breast Aspirator in Breast Cancer, Preneoplastic Conditions, BRCA, sponsored by Atossa Therapeutics, Inc.. Withdrawn at 2 sites in Israel. Open to female participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-25.

Sponsored by Atossa Therapeutics, Inc. · Phase 3, Interventional, and Screening

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
30 Years to 55 Years
Sex
Female
01

Study summary

The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology. Including collecting, processing and shipping samples, training staff, processing samples, sample interpretation and accurate and timely reporting in a manner resembling routine clinical use. The study will include a subset of patients who are known carriers of a BRCA germline mutation. NAF from this subset will be submitted for molecular testing in addition to cytology.

02

Conditions studied

  • Breast Cancer, Preneoplastic Conditions, BRCA
03

In context

Breast Neoplasms

12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, female, age 30-55 years, from whom bi-lateral specimens can be obtained.

    The following additional considerations apply:

    • Women with prior mastectomy/lumpectomy may be considered for NAF-collection in the contralateral (non-operated) breast only if they were:

      • Stage I or Stage II at the time of surgery;
      • Have completed any and all hormonal therapy, chemotherapy, or targeted therapy at least one year prior to inclusion;
      • Are considered disease-free (NED- No Evidence of Disease) at the time of study entry;
    • Women under the age 30 may be enrolled if they are within 10 years of the age at diagnosis of breast cancer in a first-degree relative. No subject under the age of 21 may be enrolled.
  2. Any woman for whom NAF-cytology testing is considered to be beneficial by her physician. This includes, but is not limited to women with first- and/or second degree relatives with breast- or ovarian cancer. Known presence of a BRCA-1 or BRCA-2 germline mutation is allowed but not required. If known, any such mutation will be noted on the Case Report Form. The protocol does not provide for testing of women without known germ-line mutations.
  3. Non-lactating and non-pregnant.
  4. Good general health as determined by medical history, breast disease/cancer history, and clinical breast exam.
  5. Willing to give informed consent and follow study procedures as directed.

Exclusion criteria

Exclusion Criteria

  1. Medical condition/psychiatric conditions making subjects a poor candidate for study, as determined by the Principal Investigator.
  2. Pregnancy or suspicion of pregnancy.
  3. Open cutaneous wounds or atopic dermatitis in the area of the nipple-areolar complex.
  4. No or inverted nipple on the breast unfit for fluid collection, or significant prior surgery in the area of the nipple-areolar complex.
  5. Participation in an investigational drug or device study less than 30 days prior to enrollment in this study.
  6. Pregnancy, childbirth, or lactation less than 90 days prior to enrollment in this study.
  7. Acute illness, including taking antibiotics, analgesics, antipyretics and/or cold medications less than 7 days prior to enrollment in this study.
05

Study design

Phase
Phase 3
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection

    Nipple Aspirate is collected using the ForeCYTE Breast Aspirator

    Device: ForeCYTE Breast Aspirator

Interventions

  • DeviceForeCYTE Breast Aspirator
06

What researchers measure

Primary outcomes

  1. NAF cytological classification(s), according to the modified King Classification.

    Time frame: 1 day (single time point)

Secondary outcomes

  1. The IBIS (Tyrer-Cuzick) risk score (10-year and lifetime breast cancer risk estimate.

    Time frame: 1 day (single time point)

  2. Safety, as reported by adverse events experienced after NAF collection with ForeCYTE Breast Aspirator

    Time frame: 1 day (single time point)

  3. micro-RNA (subgroup analysis of BRCA mutation carriers only)

    development of micro-RNA panel that signals the transition to breast cancer

    Time frame: 1 day (single time point)

07

Study locations

2 sites
  • The BARUCH PADEH Medical Center
    Poria – Neve Oved, Lower Galilee 15208, Israel
  • Ziv Medical Center
    Safed, Upper Galilee 13100, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02539615
Lead sponsor
Atossa Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2015
Start date
Sep 2015
Primary completion
Dec 2015 (estimated)
Completion
Mar 2016 (estimated)
Last update
Jan 25, 2016

Study contacts

Jelle Kylstra
study director · Atossa Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion